IMPACT Therapeutics grants Pharmanovia exclusive $488m rights to senaparib
IMPACT Therapeutics and Pharmanovia have entered an exclusive licensing deal worth up to $488.3m, giving Pharmanovia rights to manufacture, develop, and commercialise senaparib in 66 countries.
Read the full article on the original site.
Read Full Article